K
Kelonia Therapeutics
In vivo CAR-T therapies via targeted gene delivery
About Kelonia Therapeutics
Kelonia Therapeutics is a clinical-stage biotechnology company developing genetic medicines that reprogram a patient's own immune cells inside the body. Its work centres on in vivo CAR-T cell therapy, an approach intended to remove the need to harvest, engineer and reinfuse cells outside the body, which is how currently marketed cell therapies are made.
The company's platform uses specially engineered viral particles that deliver genetic material precisely to targeted cell types. Once delivered, the genetic payload instructs T cells to produce a new cancer-fighting receptor, turning them into CAR-T cells directly in the patient. Because the treatment is designed as a one-time intravenous infusion that does not require chemotherapy-based preconditioning, it aims to offer an off-the-shelf alternative that could be administered more widely than personalised ex vivo cell therapies, which are largely limited to specialised academic medical centres.
Kelonia's lead programme, KLN-1010, is an in vivo anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma, a blood cancer, and is being evaluated in the Phase 1 inMMyCAR study. Beyond multiple myeloma, the delivery technology is being explored for other haematological cancers and potentially solid tumours, and has also been applied to immuno-oncology research programmes with industry partners.
The company describes a patient-first mission focused on making potentially life-saving genetic medicines accessible to more patients. Kelonia now operates as part of Eli Lilly and Company.
Source: Dealroom company dataOpen roles
Kelonia Therapeutics in the Boston ecosystem
The Kelonia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Venrock
Horizons Ventures
Alta Partners
Series B and later2 investors entered at this stage
- FCFrench National Centre for Scientific Research - CNRS
- MTMassachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Patents
6 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Kelonia Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Eli Lilly acquires Kelonia Therapeutics for $3,250M (June 2026)

